VerifiedRx

We all know that clinician burnout negatively impacts the quality of patient care. That's why pharmacy residency accrediting bodies now emphasize resident well-being and professional sustainability as core components of residency training earlier in clinician careers. The American Society of Health-System Pharmacists (ASHP) Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies include a formal requirement for programs to address resilience, well-being, and burnout prevention, reflecting the increasing recognition of burnout in healthcare. Joining us to talk that out are Tony Huke, Senior Pharmacy Executive Director with Vizient Pharmacy Advisory Solutions and Kendra Gage, Inpatient Clinical Pharmacist and the PGY 1 Residency Program Director at UCHealth, University of Colorado Hospital in Aurora, Colorado.   Guest speakers:  Tony Huke, PharmD, BCPS, FASHP Senior Pharmacy Executive Director Vizient Pharmacy Advisory Solutions   Kendra Gage, PharmD, BCPS Inpatient Clinical Pharmacist PGY1 Pharmacy Residency Program Director UCHealth   Host:  Kerry Schwarz, PharmD, MPH  Senior Clinical Manager, Evidence-Based Medicine and Outcomes Center for Pharmacy Practice Excellence (CPPE)   Show Notes:  [01:11-03:25] What's new at the national level in terms of pharmacy resident resiliency and well-being [03:26-03:56] The intentionality of well-being in pharmacy residency programs [03:57-05:12] Examples from Kendra's program [05:13-06:40]  Program expectations to address resilience [06:41-08:33]  Assessment and potential metrics of resiliency programs [08:34-11:06]  The role of pharmacy leadership and residency program directors in resiliency [11:07-12:34] Impact of resiliency programs so far   Links | Resources: Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Information on COVID vaccines is moving fast. On May 27th, HHS Secretary Robert F. Kennedy Jr. announced that COVID vaccines will no longer be universally recommended for healthy children or healthy pregnant women. That's a big shift, and understandably, it's raised a lot of questions. We're going to cut through the noise and take a look at where things really stand, who's getting vaccinated, how current guidance is evolving, and what this means for both children and adults as we look ahead to the next respiratory season.  Joining us to help sort it all out is Dr. John Schoen, Senior Clinical Manager of Drug Information at Vizient.     Guest speakers:  John Schoen, PharmD, BCPS  Senior Clinical Manager of Drug Information   Vizient Center for Pharmacy Practice Excellence    Host:  Stacy Lauderdale, PharmD, BCPS  Associate Vice President Vizient Center for Pharmacy Practice Excellence    Show Notes:  [01:38-05:32] What changed in the recent CDC update for healthy children [05:33-09:32] Discussion of COVID-19 outcomes and vaccination in children [09:33-11:47] Specific risk factors for pediatric patients [11:48-12:47] Is the US an outlier for not universally recommending the COVID-19 vaccine for healthy children and making no recommendation in healthy pregnant women? [12:48-14:03] The FDA's proposed regulatory framework for COVID-19 vaccine approval [14:04-15:18] FDA's approach to implementing revised requirements for randomized controlled trials [15:19-16:57] Key discussion points from the May meeting of the Vaccines and Related Biological Products Advisory Committee [17:00-18:27] Topics requiring further clarification about COVID-19 vaccine   Links | Resources: Vizient resources: Minute Market Insight: Potential ACIP COVID-19 recommendation changes April 2025: https://www.vizientinc.com/download?342668 Minute Market Insight: May 2025 COVID-19 vaccine recommendation and policy updates: https://www.vizientinc.com/download?352336 Additional resources: FDA perspective piece published in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMsb2506929 ACIP meeting information: https://www.cdc.gov/acip/meetings/index.html CDC childhood immunization schedule: https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html CDC adult immunization schedule by medical condition: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html CDC RESP-NET: https://www.cdc.gov/resp-net/dashboard/ WHO COVID-19 dashboard: https://data.who.int/dashboards/covid19/deaths MMWR - COVID-19–Associated Hospitalizations and Maternal Vaccination Among Infants Aged

Pharmacy reverse distributors play a key role in making pharmaceutical returns more efficient, helping with processing, financial settlements and delivering helpful data. They're in a unique spot to support efforts to prevent diversion, speed up inventory returns, and even contribute to sustainability goals. Kyle Hoelting, director of pharmacy supply assurance and stewardship at Vizient, along with Paige Ivey, senior national accounts director, and Houston Blankinship, senior director of customer experience for healthcare product operations at Inmar Intelligence join host Carolyn Liptak, pharmacy executive director in Vizient Center for Pharmacy Practice Excellence and host for today's conversation.   Guest speakers:  Kyle Hoelting, Pharm.D, BCPS  Director, Pharmacy Supply Assurance & Stewardship Vizient Center for Pharmacy Practice Excellence   Paige Ivey Senior National Accounts Director Inmar Intelligence   Houston Blankenship Senior Director of Customer Experience for Healthcare Product Operations Inmar Intelligence   Host:  Carolyn Liptak, MBA, RPh  Pharmacy Executive Director  Vizient   Show Notes:  [01:05-03:33] Background for Kyle, Paige, Houston [03:34-05:10] How the pharmaceutical supply chain works and how everything is interconnected [05:10-09:32] How reverse distribution specifically supports pharmacy operations [09:33-11:16] How data that comes from reverse distribution can offer some great insights for pharmacy leaders [11:58-13:57] How data that comes from reverse distribution can give insight to drug shortages [13:58-16:42] Inmar's role with insight into drug shortages [16:43-21:05] Go-to resources for those wanting to explore more on stewardship and protective purchases   Links | Resources: Drug shortage stewardship: A novel solution for an old problem Vizient Essential Medications List Vizient Key performance indicators for the management of drug shortages   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Recently, there has been a lot of interest generated by a new FDA approval. Suzetrigine (Journavx) was recently approved by the US Food and Drug Administration for the management of pain. Although there is a lot of excitement about having a new tool in the toolbox, there are certain limitations that are important to consider. In this episode of Verified Rx, Dave Peterson, pharmacist and drug information specialist for the University of Utah Health joins us to discuss this exciting new non opioid medication.   Guest speakers:  Dave Peterson, PharmD, BCPS Drug Information Specialist University of Utah Drug Information Service   Host:  Kerry Schwarz, PharmD, MPH Senior Clinical Manager, Evidence-Based Medicine and Outcomes Center for Pharmacy Practice Excellence (CPPE) VerifiedRx Host   Show Notes:  [00:54-02:24] Information about Suzetrigine [02:25-04:06] What distinguishes suzetrigine from other non-opioid analgesics [04:07-05:09] What suzetrigine is indicated for [05:10-06:14] How suzetrigine is being studied [06:15-08:40] Surgical models and the endpoints that we commonly see in these studies [08:41-10:25] Making sense of discordant study results [10:26-12:02] Moving beyond the evidence to real world utilization of suzetrigine [12:03-14:03] How cost factors into real-world utilization [14:04-16:21] What Dave is keeping his eye on in terms of clinical concerns [16:22-17:28] What Dave is excited about with the advent of suzetrigine   Links | Resources: No pain, much gain?   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

The 340B program has been active for over 30 years and is dynamic and evolving. Dr. Greg Medley, Senior Director, 340B Drug Pricing Program Services at Vizient joins host Carolyn Liptak, Pharmacy Executive Director with the Vizient Center for Pharmacy Practice Excellence to discuss the impact of the most recent executive order on the 340b program.    Guest speakers:  Greg Medley, PharmD Senior Director, 340B Drug Pricing Program Services Vizient Inc.   Host:  Carolyn Liptak, MBA, , BS Pharm Pharmacy Executive Director, Center for Pharmacy Practice Excellence Vizient Inc.   Show Notes: [00:53-01:26] Dr. Medley background information  [01:27-03:17] What is outlined in the executive order [03:18-05:27] Basics of how 340B works and why its under fire [05:28-09:36] How this new executive order pertains to the 340B program  [09:37-13:01] What is learned from the comments on these changes [13:02-14:07] Where can listeners go now to get more information?   Links | Resources: JAMA article Click Here Fact Sheet: President Donald J. Trump Announces Actions to Lower Prescription Drug Prices  Click Here Lowering Drug Prices by Once Again Putting Americans First  Click Here   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Traditional drug spending in the U.S. has surpassed specialty drug spending, and the primary force behind this trend is GLP-1 receptor agonists. These incretin-based therapies are transforming both the clinical and economic landscapes, from diabetes to obesity. In this episode of the Center for Pharmacy Practice Excellence's VerifiedRx podcast, host Tori Richie, Senior Consulting Director of Intelligence at Sg2 is joined by Vizient colleagues Stacy Lauderdale, AVP of Evidence-Based Medicine, Heather Pace, Senior Clinical Manager of Ambulatory Care, and Emily Fitt, Intelligence Consultant at Sg2. They delve into a comprehensive discussion on GLP-1s, covering topics from telehealth services and patient management strategies to the unique attributes that set these therapies apart. Grab your coffee and get comfortable. This isn't just a conversation; it's a front-row seat to how GLP-1s are reshaping the future of obesity management.   Guest speakers:  Stacy Lauderdale, Pharm.D, BCPS Associate Vice President Vizient Center for Pharmacy Practice Excellence VerifiedRx Host   Heather Pace, Pharm.D Sr. Clinical Manager of Ambulatory Care, Vizient Center for Pharmacy Practice Excellence   Emily Fitt, MHA, MPH Consultant Sg2   Host:  Tori Richie Senior Consulting Director, Intelligence Sg2 Sg2 Perspectives Host   Show Notes:  [02:24-04:50] How GLP-1 medications differ from traditional treatments and shift from use in diabetes to obesity management [04:51-05:54] The most common side effects of GLP-1 therapies and how clinicians can effectively manage patients [05:55-08:49] Treatment teams for obesity management and the role of the pharmacist in the management of GLP-1 medications [08:50-10:51] Challenges providers face integrating GLP-1 medications into practice [10:16-13:20] Quality or outcome concerns with individuals who receive GLP-1 medications from telehealth providers [13:21-15:01] Trends shaping this landscape [15:02-21:14] Best practices that providers should deploy   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Widespread vaccination efforts declared measles eliminated in the United States in 2000. However, recent outbreaks have reignited public health concerns. The country is experiencing a growing number of measles cases with clusters reported in several states. A highly contagious virus, measles, poses serious risks, especially to unvaccinated individuals and vulnerable patient populations. Dr. John Schoen, Senior Clinical Manager of Drug Information at the Vizient Center for Pharmacy Practice Excellence, discusses the current outbreak, measles vaccine strategies, and answers questions about prevention and public health impact with Stacy Lauderdale, Associate Vice President at the Vizient Center for Pharmacy Practice Excellence and your VerifiedRx program host.   Guest speakers:  John Schoen, Pharm.D, BCPS Senior Clinical Manager of Drug Information Vizient Center for Pharmacy Practice Excellence   Host:  Stacy Lauderdale, Pharm.D, BCPS Associate Vice President Vizient Center for Pharmacy Practice Excellence   Show Notes:  [01:12-03:30] Are we in an unprecedented situation in the United States? [03:31-05:49] A brief overview about measles [05:50-08:03] Overview of the MMR vaccine [08:04-10:15] MMR vaccination rate in the United States [10:16-12:27] Is there a link between autism and MMR vaccine [12:28-14:47] Does the MMR vaccine cause measles? [14:48-18:04] 1 vs. 2 doses of the MMR vaccine in adults [18:05-21:25] Measles postexposure prophylaxis [21:26-23:40] Vitamin A and measles   Links | Resources:  Vizient Resources Evidence Bites: 2025 Measles Outbreak Resources Measles cases and outbreaks: https://www.cdc.gov/measles/data-research/index.html 2013 MMWR measles recommendations: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm#Tab3 CDC measles vaccine recommendations: https://www.cdc.gov/measles/hcp/vaccine-considerations/index.html#cdc_generic_section_5-post-exposure-prophylaxis-for-measles HAN alert 2025 outbreak: https://www.cdc.gov/han/2025/han00522.html American Academy of Pediatrics recommendations: https://publications.aap.org/redbook/book/755/chapter/14079321/Measles?autologincheck=redirected Information about the MMR vaccines: https://www.cdc.gov/vaccines/vpd/mmr/hcp/about.htm   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Prothrombin complex concentrates (PCCs) are frequently used off label for the management of factor Xa inhibitor-associated major bleeding. In 2018, accelerated approval was granted for andexanet alfa, a specific factor Xa inhibitor reversal agent, for reversal of apixaban and rivaroxaban in the setting of life-threatening or uncontrolled bleeding. Following accelerated approval, some clinical practice guidelines were updated to include recommendations for andexanet alfa preferentially over PCCs for reversal of life-threatening or uncontrolled bleeding due to rivaroxaban or apixaban. Other guidelines stated no preference of andexanet alfa over PCC. In 2020, Vizient convened an expert panel to critically appraise the literature and provide consensus-based, expert opinions on the utilization of pharmacological reversal agents for factor Xa-related major bleeding. Since then, the body of literature evaluating these agents has expanded to include a randomized controlled trial, ANNEXa-I, the results of which were submitted to the US Food and Drug Administration to convert the approval of andexanet alfa from accelerated to full approval. Dr. Lisa Baumann-Kreuziger, Associate Professor of Hematology and Oncology, Medical College of Wisconsin and medical director of the Antithrombotic Therapy Management Program at Froedtert Health discusses the current status of management of factor Xa inhibitor-associated major bleeding with Dr. Kerry Schwarz, Senior Clinical Manager of Evidence-Based Medicine and Outcomes with the Vizient Center for Pharmacy Practice Excellence, and your program host.   Guest speakers:  Liza Baumann-Kreuziger, MD, MS Investigator, Blood Research Institute, Versiti  Associate Professor of Hematology and Oncology, Medical College of Wisconsin Medical Director, Antithrombotic Therapy Management Program at Froedtert Health   Host:  Kerry Schwarz, Pharm.D, MPH Senior Clinical Manager of Evidence-Based Medicine and Outcomes  Vizient Center for Pharmacy Practice Excellence   Show Notes: [02:25-04:26] The current state of hemostatic management in the setting of factor Xa inhibitor-related major bleeding [04:27- 05:35] Limitations of available evidence making clinical practice and formulary decision making so challenging [05:35 – 10:52] Publication of the first randomized controlled trial, ANNEXa-I, comparing andexanet alfa to usual care [10:52-14:49] Meeting of the FDA advisory committee and subsequent complete response letter [14:50-16:45] How we can approach clinical management of patients and formulary decision-making in the current state   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Drug shortages continue to pose significant challenges for hospitals and health systems. While they gained national attention during the COVID-19 pandemic, pharmacy departments have managed them for decades. During high-profile shortages, institutions must rapidly establish command centers, engage stakeholders, and implement plans for frontline staff. Once resolved, shortages often recede from immediate focus until the next crisis emerges. However, pharmacy departments consistently manage shortages on a daily basis, often without recognition. Dr. Kyle Hoelting, Sr. Clinical Manager of Drug Information and Drug Shortages at Vizient, Dr. Heather Warhurst, Director of Drug Use Policy, Quality Initiative and Regulatory at IU Health, and Dr. Chris Nagy, Medication Sourcing and Supply Pharmacist at Intermountain Health join us to discuss a Vizient workgroup project designed to measure the impact of drug shortages and highlight the crucial role of pharmacists in their management.   Guest speakers:  Heather Warhurst, Pharm.D, MHA Director of Drug Use Policy, Quality Initiative and Regulatory IU Health   Chris Nagy, Pharm.D, BCPS Medication Sourcing and Supply Pharmacist Intermountain Health   Kyle Holting, Pharm.D, BCPS Senior Clinical Manager of Drug Information Vizient Center for Pharmacy Practice Excellence   Host: Stacy Lauderdale, Pharm.D, BCPS Associate Vice President Vizient Center for Pharmacy Practice Excellence VerifiedRx Host   Show Notes:  [01:18-02:29] Heather and Chris introductions [02:30-04:00] Vizient drug shortage key performance indicators (KPI) workgroup series [04:01-10:04] Labor and Inventory drug shortage KPIs [07:50-16:56] Patient Safety and Stress to Front Line Staff drug shortage KPIs [16:57-18:32] Call to Action   Links | Resources:  Key performance indicators for the management of drug shortages   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

The widespread use of pneumococcal conjugate vaccine (PCV) in children has dramatically lowered the incidence of pneumococcal disease through direct and indirect effects. Despite this progress, pneumococcal pneumonia still leads to more than 200,000 adult hospitalizations annually in the United States. Older adults, individuals with underlying health conditions, and certain racial groups continue to experience higher rates of pneumococcal disease. Dr. John Schoen, Senior Clinical Manager of Drug Information at the Vizient Center for Pharmacy Practice Excellence, joins Program Host Stacy Lauderdale to discuss the newest adult pneumococcal vaccine, PCV21, and recent updates to age-based pneumococcal vaccine recommendations.   Guest speakers:  John Schoen, Pharm.D, BCPS Senior Clinical Manager of Drug Information Vizient Center for Pharmacy Practice Excellence   Host:  Stacy Lauderdale, Pharm.D, BCPS Associate Vice President Vizient Center for Pharmacy Practice Excellence VerifiedRx Host   Show Notes:  [01:25-02:53] Background on PCV21 [02:54-07:56] Difference between PCV20 and PCV21 [07:57-16:15] Discussing the new ACIP recommendation to move the universal age for pneumococcal vaccination from 65 years of age down to 50 years of age and older [08:31-16:15] Why a healthy 50-year-old who has no risk factors for invasive pneumococcal disease should get a pneumococcal vaccination [16:16-17:57] Summary of other changes in the most recent MMWR [17:58-19:34] What organizations consider when selecting specific pneumococcal vaccines [19:35-21:18] What's in the pipeline for  pneumococcal vaccines   Links | Resources:  Publicly available resources Previous VerifiedRx podcasts on pneumococcal vaccines: What's pneu with pneumococcal vaccines? – March 29, 2022 What's pneu part 2: pneumococcal vaccines update – February 13, 2024 January 2024 MMWR - ACIP recommendations for the use of PCV in adults ≥ 50 years of age Vizient client exclusive resources 2025 pneumococcal vaccines side-by-side comparison   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Prescription opioids continue to be the most frequently misused prescription drugs in the United States, having caused nearly 300,000 deaths over the past two decades. Signed into law in 2022, the No Pain Act expands Medicare reimbursement for specific non-opioid pain management options. Carolyn Liptak, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence, and Dr. Phil Mentler, Senior Consulting Director at Vizient join Program Host Stacy Lauderdale to discuss the implications of the No Pain Act, which took effect on January 1, 2025.   Guest speakers:  Carolyn Liptak, MBA, RPh Pharmacy Executive Director Vizient   Phillipe Mentler, Pharm.D, BCPS Senior Consulting Director Vizient   Host:  Stacy Lauderdale, Pharm.D, BCPS Associate Vice President Vizient VerifiedRx Host    Show Notes:  [01:49-03:48] Background on the No Pain Act [03:49-05:03] What is new as of January 1, 2025 [05:04-05:37] The difference between a hospital outpatient department versus an ambulatory surgical center [05:38-06:30] Other drugs and or devices that are on the list other than Exparel [06:31-07:42] What specifically prevents multi modal drugs and therapy from being added to the list [07:43-08:24] Specific language that needs to be included in the FDA labeling for non-opioids to be considered for reimbursement under the Act [08:25-10:50] Reimbursement basics of the NO PAIN Act [14:32-15:44] Reimbursement [15:45-17:04] The importance of opioids in pain management   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Historically, Vizient has published the Pharmacy Market Outlook biannually. This year, we are introducing the Spend Management Outlook, which integrates the comprehensive insights from the Pharmacy Market Outlook with the Vizient Budget Impact Report. This new report enhances strategic planning by aligning pricing projections across the healthcare supply chain and providing key market insights. Dr. Carina Dolan, Associate Vice President of Clinical Oncology, Pharmacoeconomics, & Market Insights, and Jeff King, Director of Research and Intelligence at Vizient, join Program Host Carolyn Liptak to discuss the unique features and critical importance of the new Spend Management Outlook.   Guest speakers:  Carina Dolan, Pharm. D., MS Pharm, BCOP Associate Vice President, Clinical Oncology, Pharmacoeconomics and Market Insights Vizient   Jeff King Research and Intelligence Director Vizient   Host: Carolyn Liptak, MBA, BS Pharm VerifiedRx Host   Show Notes:  [01:06-01:56] Jeff's background and role [01:57-02:50] The transition from Pharmacy Market Outlook and Budget Impact Report to Spend Management Outlook [02:51-03:28] Defining spend management [03:29-04:43] Key insights into spend management categories med-surg and laboratory [04:44-06:01] Key insights into spend management categories Capital equipment and physician preferences insights [06:02-07:23] Enhancements to pharmacy projections of this edition [07:24-08:39] Spend management projection methodology [08:40-09:34] The spend management projections   Links | Resources: Spend Management Outlook   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

We anticipate there will be some policy changes and important issues to watch with the inauguration of the 47th president of the United States. Vizient's office of public policy and government relations monitors, educates and advocates on key items of interest. They share informative updates, comment on proposed rules from agencies like the Centers for Medicare and Medicaid Services and work with Congress on legislative priorities. Jenna Stern, Associate Vice President of Regulatory Affairs and Public Policy at Vizient joins Program Host Carolyn Liptak to discuss the change over.   Guest speakers:  Jenna Stern Associate Vice President of Regulatory Affairs and Public Policy Vizient   Host: Carolyn Liptak, MBA, RPh VerifiedRx Host    Show Notes:  [00:56-01:15] Jenna's background  [01:16-02:38] Anticipation in DC since November [02:39-04:26] What we should anticipate with the new Congress [04:27-08:10] Trade and Tariffs [08:11-10:37] What we should anticipate with the Executive Branch [10:38-12:48] Policies to watch during transition [12:48-13:34] Where listeners go for more information [13:34-16:12] What issues are important to the new Congress   Links | Resources:  Vizient Public Policy and Government Relations  Vizient advocacy letters and Congressional statements  Legislative and regulatory summaries  China Tariffs document   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

The pharmacy infusion market continues to shift administration of biologics and specialty medications to the home or other lower-cost sites of care. Much of this is driven by payers. This change brings clinical, patient, economic, and information system considerations. Dr. Steve Kennedy, Senior Consulting Director at Vizient Pharmacy Advisory Solutions joins Program Host Gretchen Brummel to discuss sites of care.   Guest speakers:  Steve Kennedy, PharmD Executive Director, Pharmacy Advisory Solutions Vizient Host:  Gretchen Brummel, PharmD, BCPS  Verified Rx Host   Show Notes:  [00:44-01:25] Steve's background  [01:26-02:18] How has the industry evolved over your career [02:19-03:51] Why there is a shift in where these medications are administered [03:52-06:36] Who's watching these patients at home or in other non-hospital-based infusion settings  [06:37-7:34] How patients respond to change in site of care [7:35-8:19] Is this shift realistic in rural areas where care outside of a hospital setting might not be consistently available [8:20-9:30] Advocating or negotiating for patients when it doesn't align with the payer's interest [9:31-10:23] How white bagging factors in [10:24-11:32] What front line pharmacy staff needs to know   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed    

Human rabies cases are fortunately rare in the US. Access to pre- and post-exposure prophylaxis, and domestic animal vaccination programs, drive this public health success. This comes at a financial and human resources cost. Dr. Kyle Weant, clinical assistant professor and an emergency medical clinical pharmacy specialist at the University of South Carolina College of Pharmacy and Dr. Philippe Mentler, senior consulting director, join host Gretchen Brummel to discuss the use of rabies immune globulin and rabies vaccine in patients who have been exposed and provide treatment pearls for frontline pharmacy practioners.   Guest speakers: Kyle Weant, PharmD, BCPS, BCCCP, FCCP Clinical Assistant Professor and an Emergency Medical Clinical Pharmacy Specialist University of South Carolina College of Pharmacy   Philippe Mentler, PharmD, BCPS Senior Consulting Director Vizient   Host:  Gretchen Brummel, PharmD, BCPS   Show Notes:  [00:54-01:17] Kyle's background information  [01:18-03:31] Rabies as a disease [03:32-05:13] Public Awareness [05:14-07:06] Options right now for post-exposure prophylaxis [07:07-10:01] Thoughts on dose rounding [10:02-10:13] Is rabies immunoglobulin considered an essential medication that everyone should stock in their hospital pharmacy [10:14-11:30] Who should be administering these drugs? And who's ensuring follow up of these patients? [11:31-14:31] Potential pitfalls in patient management [14:32-18:12] What should our frontline pharmacy staff know about post-exposure prophylaxis   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Data dominate nearly every sector and drug shortages are an area to leverage data solutions. Stephen Colvill, Senior Policy Advisor for Medical Supply Chains, The White House Domestic Policy Council and Dr Nikola Markoski, Vizient Manager of Pharmacy Analytics and Clinical Insights, join host Gretchen Brummel to explore novel approaches and future implications for data use cases in drug shortages.   Guest speakers:  Stephen Colvill Senior Policy Advisor for Medical Supply Chains, Domestic Policy Council The White House, Domestic Policy Council This podcast was recorded in December 2023 prior to Stephen joining the federal government. The opinions expressed are the author's own and do not necessarily reflect the views of  the United States government or any agency thereof. At the time of recording, Stephen was Executive Director of RISCS and Assistant Research Director at the Duke-Margolis Institute for Health Policy.   Nikola Markoski, PharmD, MBA, DPLA Manager of Pharmacy Analytics and Clinical Insights Vizient   VerifiedRx Host:  Gretchen Brummel, PharmD, BCPS   Show Notes:  [00:36-02:23] Guest's background information  [02:24-05:44] How using data can change the discussion of drug shortages [05:45-09:23] Approaches that have been attempted so far in the data space [09:24-12:01] Where things are going in the future [12:02-15:23] How we get everybody on the same page   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Chemotherapy is a vital treatment for cancer patients, but high medication prices often cause issues and may even prompt patients to skip therapy. Various factors influence the cost of chemotherapy drugs, including research and development, manufacturing complexity, and regulatory compliance. Limited use implications further complicate the market. Dr. Michele Rice, Senior Pharmacy Executive with Vizient Pharmacy Advisory Solutions, joins us today to discuss these factors in depth.   Guest speakers:  Michele Rice, PharmD, MS Senior Consulting Solutions Director  Vizient Pharmacy Advisory Solutions Host:  Gretchen Brummel, PharmD, BCPS   Verified Rx Host Show Notes:  [00:47-01:31] Guest's background information  [01:32-03:41 ] What's happening in the industry now [03:42-05:15] How this ultimately affects patients [05:20-06:26] How pharmacists can assist patients with this difficult to navigate scenario or situation [06:27-07:35] What patients should know about this issue [07:36-08:09] How to improve the system [08:10-08:44] What does the future hold   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed    

Baxter's Intravenous Fluids North Cove Plant was impacted in September by Hurricane Helene. Although Baxter implemented a hurricane preparedness plan, a levy breach and bridge collapse forced a complete shutdown. Intravenous fluids are now on allocation as the plant remains shuttered. Multiple actions by the FDA and Baxter are in effect to improve supply for these fluids. Vizient colleagues Katie Korte, VP Assurance and Continuity Team and Kyle Hoelting, Senior Clinical Manager of Drug Information and Shortages join Stacy Lauderdale, Associate Vice president of Evidence-based Medicine today to discuss lessons learned from this and past supply disruptions, ongoing efforts by the FDA to improve supplies and the supply outlook for the next four to eight weeks   Guest speakers:  Katie Korte, PharmD, MHA VP Assurance and Continuity Team Vizient   Kyle Holting, PharmD, BCPS Senior Clinical Manager of Drug Information and Shortages Vizient Center for Pharmacy Practice Excellence   Host:  Stacy Lauderdale, PharmD, BCPS Associate Vice president of Evidence-based Medicine Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:57-01:27] Guest's background information  [01:28-04:33] Recent supply disruptions [04:34-05:54] What Vizient has learned from past disruptions [05:55-09:30] What providers have learned from these shortages [09:31-13:42] What the FDA is doing to assist with this shortage [13:43-18:23] What the trajectory of this shortage looks like over the next four to eight weeks [18:24-19:45] Most important thing to emphasize to our listeners as they continue to handle this fluid shortage   Links | Resources:  Vizient's IV push list: Click here Vizient's IV fluid conservation strategies: Click here Baxter's North Cove facility website: Click here FDA's Baxter North Cove facility website: Click here   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

The Pharmacy Vision Awards at Vizient celebrate values and achievements of our program participants. Elham Amiri, pharmacy informatics project manager at UCSF Health, is a recipient of the professional excellence award, given to an individual who demonstrates leadership, strategic contribution and commitment to ongoing learning and development. Elham and Dr. Noelle Chapman, vice president, chief pharmacy officer and COO at UCSF Health, join us today to discuss their award-winning program.   Guest speakers:  Elham Amiri, CPhT, CSPT, BS Pharmacy Informatics Project Manager  UCSF Health Noelle Chapman, PharmD, MBA Vice president, Chief Pharmacy Officer and COO  UCSF Health Host:  Carolyn Liptak, BS Pharmacy, MBA   Pharmacy Executive Director   Vizient Center for Pharmacy Practice Excellence     Show Notes:  [00:52-02:07] Guest's background information  [02:08-03:32] Their great work at UCSF Health [03:33-05:49] How their work contributed to the Pharmacy Value Improvement Program [05:50-07:27] Taking a roll and running with it [07:28-09:25] How UCSF supports professional development [09:25-10:24] How patients benefit from this model [10:25-13:45] What does the future hold   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed  

We emerged from the COVID -19 pandemic in 2022 to headlines about unseasonably early spikes in respiratory syncytial virus and concerns and threats of a triple pandemic of CV19, influenza, and RSV.  Fortunately, there's been no triple pandemic, but what has emerged is multiple first-time vaccine approvals for RSV. Dr. John Schoen, Senior Manager of Drug Information at The Vizient Center for Phamacy Practice Excellence joins his colleague and Program Host Stacy Lauderdale, Associate Vice President of Evidence-Based Medicine to discuss the use of the RSV vaccines.   Guest speakers:  John Schoen, PharmD, BCPS Senior Manager of Drug Information  Vizient Center for Pharmacy Practice Excellence   Host: Stacy Lauderdale, PharmD, BCPS Associate Vice President of Evidence-Based Medicine  Vizient Center for Pharmacy Practice Excellence VerifiedRx Host   Show Notes:  [00:55-01:46] John's background  [01:47 -03:15] The RSV disease burden in older adults, and risk factors [03:16-04:42] The relative disease severity of RSV versus influenza [04:43-07:04] Vaccine uptake during the last RSV season [07:05-8:35] Efficacy of the RSV vaccines in observational data compared to the clinical trials [8:36-11:22] Changes in ACIP recommendations [11:23-13:14] Potential benefits of RSV vaccination for ages older than 75 [13:15-15:32] Potential adverse reactions of RSV vaccines [15:33-18:31] Comparisons of the RSV vaccines [18:32-20:46] Are patients going to need more than one RSV vaccine?   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

The Pharmacy Vision Awards at Vizient celebrate values and achievements of our program participants. The innovation award is granted to an individual or group who works with others to implement an innovative approach to a challenging patient care or operational practice issue. The 2023 winner, Ochsner Health, represented by Dr. Lisa Boothby, Director of Pharmacy at Ochsner Medical Center - West Bank Campus, Dr. Johlee Odinet, System Medication Safety Officer and Veronica Theriot, Director of MedSurg/Tele Stepdown Unit discuss with host Gretchen Brummel their program aimed at expanding pharmacists' responsibilities to include medication administration.   Guest speakers:  Lisa Boothby, PharmD, MBA Director of Pharmacy Ochsner Medical Center West Bank Campus   Johlee Odinet, PharmD, BCPS, CPPS System Medication Safety Officer Ochsner Medical Center West Bank Campus   Veronica Theriot, RN Director of MedSurg/Tele Stepdown Unit Ochsner Medical Center West Bank Campus   Host:  Gretchen Brummel, PharmD, BCPS  VerifiedRx   Show Notes:  [00:55-02:02] Guest's background information  [02:03-03:17] Ochsner Information [03:18-05:30] People not mentioned who were contributors to their success [05:31-07:47] Need for pharmacists' expanded role in administering medications in the inpatient setting [07:48-18:06] How Ochsner accomplishes pharmacist expanded role [18:07-23:02] Other outcomes from their work [23:03-26:00] What surprised them about the process [26:01-28:42] Advice for others wanting to implement this innovative practice   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Clinical pharmacy optimization opportunities abound, and executing on them can be enhanced when collaborating with external partners. Dr. Nikolai Dahl, program manager for medication utilization and formulary at John Muir Health, and Dr. Tony Huke, senior consulting director at Vizient, join host Gretchen Brummel to share their partnership experience and the resulting successes.   Guest speakers:  Nikolai Dahl, Pharm D Program Manager for Mediation Medication UtliazationUtilization John Muir Health Tony Huke, Pharm D, BCPS, FASHP Senior Consulting Director Vizient Host:  Gretchen Brummel, PharmD, BCPS  Verified Rx Host   Show Notes:  [00:44-01:16] How partnership came about [01:17-02:31] Nikolai's and Tony's initial thoughts about the partnership [02:32-03:24] How their work together started [03:25-3:49] Prioritizing a to-do list [03:49-4:21] Early wins [04:22-4:38] What surprised them about the engagement [04:38-6:18] Positive stories   Vizient Pharmacy Vision Awards celebrate the values and achievement of our pharmacy program participants. The Excellence in Integrated Transformational Practice award is given to a system that accelerates success in delivering high value care in the four domains of operations, quality, strategic growth, supply chain and pharmacy.  Joining us from the winning organization, UCSF Health, are Drs. Desi Kotis, Chief Pharmacy Executive, Jessica Galens, Assistant Chief Pharmacy Officer of Business Services and Erin St. Angelo, Director of Pharmacy Procurement and Contracting. They join us to share his perspective on pharmacy leadership with program host Gretchen Brummel.   Guest speakers:  Desi Kotis, Pharm D Chief Pharmacy Executive  UCSF Health Jessica Galens, Pharm D Assistant Chief Pharmacy Officer of Business Services  UCSF Health Erin St. Angelo, Pharm D Director of Pharmacy Procurement and Contracting  UCSF Health Host:  Gretchen Brummel, PharmD, BCPS  Verified Rx Host   Show Notes:  [00:56-03:41] Backgrounds and roles at UCSF [03:42-07:14] UCSF's overall approach [07:15-08:53] Background for innovative and clinical practice [08:54-10:19] Financial successes [10:20-13:17] How UCSF has been able to expand their services [13:18-14:35] Future for UCSF   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Vizient Pharmacy Vision Awards celebrate the values and achievement of our pharmacy program participants. The Excellence in Integrated Transformational Practice award is given to a system that accelerates success in delivering high value care in the four domains of operations, quality, strategic growth, supply chain and pharmacy.  Joining us from the winning organization, UCSF Health, are Drs. Desi Kotis, Chief Pharmacy Executive, Jessica Galens, Assistant Chief Pharmacy Officer of Business Services and Erin St. Angelo, Director of Pharmacy Procurement and Contracting. They join us to share his perspective on pharmacy leadership with program host Gretchen Brummel.   Guest speakers:  Desi Kotis, Pharm D Chief Pharmacy Executive  UCSF Health Jessica Galens, Pharm D Assistant Chief Pharmacy Officer of Business Services  UCSF Health Erin St. Angelo, Pharm D Director of Pharmacy Procurement and Contracting  UCSF Health Host:  Gretchen Brummel, PharmD, BCPS  Verified Rx Host   Show Notes:  [00:56-03:41] Backgrounds and roles at UCSF [03:42-07:14] UCSF's overall approach [07:15-08:53] Background for innovative and clinical practice [08:54-10:19] Financial successes [10:20-13:17] How UCSF has been able to expand their services [13:18-14:35] Future for UCSF   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed    

The Pharmacy Vision Awards at Vizient celebrate values and achievements of our program participants. The Executive Leadership Award is granted to an individual who provides strategic insight, advances leading clinical practices, and demonstrates business acumen for their entire organization. Our 2023 winner is Dr. Curtis Haas, Chief Pharmacy Officer at the University of Rochester Medical Center. He's joins us to share his perspective on pharmacy leadership with Gretchen Brummel, your program host.   Guest speakers:  Curtis Haas, Pharm D, FCCP Director of Pharmacy University of Rochester Medical Center Host:  Gretchen Brummel, PharmD, BCPS  Verified Rx Host    Show Notes:  [00:47-05:11] Curtis Haas background and why it's important [05:12-07:02] Why elevating pharmacy practice on a state and national basis is important [07:03-08:59] Results of success by placing priority on providing resources and support and encouraging innovation [09:00-12:36] What Curtis has been doing lately at the University of Rochester Medical Center that he would like to highlight [12:37-14:53] Curtis' volunteer work outside his organization   Links | Resources:  https://verifiedrx.podbean.com/e/transcendental-medication-management-transformational-practice-in-pharmacy/   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed  

Vizient publishes our Pharmacy Market Outlook twice a year. The outlook features drug price projections and key market insights to help support members' strategic planning. Drs. Jeni Hayes and Amanda Frick, both Senior Clinical Managers for Market Intelligence, join Carolyn Liptak, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence and your program host to give an early look.   Guest speakers:  Jeni Hayes, PharmD, MSPharm, BCPS Senior Clinical Manager, Market Intelligence Vizient  Amanda Frick, PharmD, BCPS Senior Clinical Manager, Market Intelligence Vizient  Host:  Carolyn Liptak, MBA, BS Pharm  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:45-02:06] Hot Topics 2024 highlighted in this Pharmacy Market Outlook  [02:07-02:50] Pipeline section looks different. What are the updates? [02:51-03:44] Looking forward to drugs being approved in 2024: afami-cel and obi-cel [03:45-4:45] New and noteworthy medication approvals [4:46 – 5:55] Cell and gene therapy agents [5:56-10:32] Therapeutic area updates 6:45 Autoimmune and inflammatory 7:16 Cardiopulmonary 7:51 Endocrine and metabolic 8:05 Hematological agents 8:26 Infectious diseases 8:47 Neurology 9:10 Oncology 10:06 Plasma [10:33 -11:29] What's the projection for this edition [11:30-12:08] Where listeners go if they want more detailed information on the outlook   Links | Resources:  Vizient Pharmacy Market Outlook provider link: Click Here Vizient Pharmacy Market Outlook highlights public version: Click Here   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed    

Vizient Pharmacy Vision Awards celebrate the values and achievements of our pharmacy members. The Excellence in Performance Improvement Award is given to an organization that achieves performance excellence and exceeds expectations in clinical, operations, specialty, retail, or 340B pharmacy. Corewell Health won award in 2023. Stephanie Field, VP, Finance – Pharmacy Business Services, and Margo Bowman, Senior Director of Clinical Pharmacy, are here from Corewell Health to discuss their award-winning program. I'm Gretchen Brummel your program host.   Guest speakers:  Stephanie Field, MBA Vice President Finance – Pharmacy Corewell Health   Margo Bowman, PharmD Senior Director of Clinical Pharmacy Corewell Health   Host:  Gretchen Brummel, PharmD, BCPS  VerifiedRx Host   Show Notes: [00:52-02:35] Background information Stephanie and Margo [02:36 - 03:46] Situation before the team started their work [03:47- 04:55] Coming up with a solution [04:56 - 06:05] The program [06:06 -09:20] Outcome improvements they have seen [09:21 - 11:14] How frontline staff responded to the program [11:15-12:18] Enhancing the program in the future.   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

The Pharmacy Vision Awards from Vizient celebrate values and achievements of our program participants. The Excellence in Clinical Practice Award is granted to an organization that implements novel clinical practices to improve patient outcomes and reduce the cost of medication utilization. Doctors Jona Banzon, Director of Outpatient Operations for infectious disease, Pooja Cerrato, Clinical Pharmacist – Travel Medicine and Infectious Diseases, and Kaitlyn Rivard, Infectious diseases Clinical Specialist all from the Cleveland Clinic, join host Gretchen Brummel, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence, to discuss their award winning travel clinic.   Guest speakers:  Jona Banzon, MD Director of Outpatient Operations for Infectious Disease Cleveland Clinic   Pooja Cerrato, PharmD Clinical Pharmacist – Travel Medicine and Infectious Diseases Cleveland Clinic   Kaitlyn Rivard, PharmD Infectious Diseases Clinical Specialist Cleveland Clinic   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence   Show Notes:  [00:59-02:29] Guests background information  [02:30-03:23] Recognition of others for this award [03:24-06:06] How Cleveland Clinic first identifed the need for a travel clinic [06:107-12:33] Pulling the clinic together [12:34-15:12] What services did the clinic eventually offer [15:13-18:01] Impact of the clinic [18:02-21:38] Barriers [21:38-23:14] Expanding the clinic [23:15-27:04] Advice for others wanting to start a travel clinic   Links | Resources: Travelers' Health | CDC What Vaccines Do I Need for Travel? (clevelandclinic.org) Pharmacy Vision Awards   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Margins are tight everywhere in healthcare, and a health system pharmacy adds value especially when led by an established chief pharmacy officer.  Jordan Dow, Chief Pharmacy Officer at Froedtert Health, Michael Oinonen, VP of Pharmacy Networks at Vizient, and our usual host Gretchen Brummel, Pharmacy Executive Director for the Vizient Center for Pharmacy Practice Excellence join guest host Carolyn Liptak, Pharmacy Executive Director with the Vizient Center for Pharmacy Practice Excellence to discuss the importance of the CPO role.   Guest speakers:  Jordan Dow, PharmD, MS, FASHP, FACHE Chief Pharmacy Officer Froedtert Health   Michael Oinonen, PharmD VP of Pharmacy Networks  Vizient   Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Host:  Carolyn Liptak, BS Pharmacy, MBA  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:54-02:53] Mike Oinonen and Jordon Dow background information  [02:54-04:31] What exactly is a Chief Pharmacy Officer and how the CPO role differs from other types of health system pharmacy leaders [04:32-08:17] Gretchen and Mike discuss their blog post on the CPO role [08:18-07:46] Does the CPO role apply to all health systems in all hospitals big or small [07:47-12:11] How prevalent is this CPO role, and its history [12:12-15:42] Benefits of having a pharmacist at the C-suite level [15:42-19:03] What an organization is mission without a CPO [19:04-21:46] Where the CPO role is going in the future   Links | Resources: A Chief Pharmacy Officer in your C-suite: Vital to health system success  Vizient Pharmacy Solutions  Pharmacy Network  HVPE  ASHP Statement on the Roles and Responsibilities of the Pharmacy Executive  Rationale for having a chief pharmacy officer in a health care organization | American Journal of Health-System Pharmacy | Oxford Academic (oup.com)  The rise of the chief pharmacy officer    Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Rural pharmacy practitioners are unique, and practicing in this setting takes a broad and deep understanding of pharmacy opportunities and challenges.  Dr. Kyle Johnicker and Dr. Samreena Rasheed, both pharmacy clinical coordinators at Northwestern Medicine overseeing small and rural hospitals join host Gretchen Brummel, Pharmacy Executive Director with the Vizient Center for Pharmacy Practice Excellence at ASHP Midyear in Anaheim to discuss their unique opportunity and challenges.   Guest speakers:  Kyle Johnicker, PharmD Pharmacy Clinical Coordinator Northwestern Medicine Kishwaukee Hospital   Samreena Rasheed, PharmD, BCPS Regional Pharmacy Clinical Coordinator Northwestern Medicine Huntley, McHenry, and Woodstock Hospitals   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:47-02:28] Dr. Johnicker and Dr. Rasheed background information  [02:29-04:10] What attracted them to rural pharmacy [04:11-05:32] Skill set necessary for rural pharmacy [05:33-07:46] Recent pharmacy successes at their organization [07:47-09:29] Where they would like to see rural pharmacy grow in the future [09:30-10:48] Advice for students or residents thinking about a career in rural pharmacy   Links | Resources:  Antimicrobial and Diagnostic Stewardship Program: Northwestern Medicine   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

The incredible staying power of drug shortages kicks the door open for full-time pharmacy roles designed to combat this issue. Dr. Austin Pytlowany, clinical pharmacist specialist in drug shortage management at Michigan Medicine and Vizient's Kyle Hoelting, senior clinical manager of drug shortages and drug information join host Gretchen Brummel, Pharmacy Executive Director with the Vizient Center for Pharmacy Practice Excellence to discuss drug shortages and drug information and share their perspectives.   Guest speakers:  Austin Pytlowany, PharmD Pharmacy Manager – Inventory and Drug Shortage Management Michigan Medicine Kyle Hoelting, PharmD, BCPS Sr. Clinical Manager of Drug Information and Shortages Vizient Center for Pharmacy Practice Excellence  Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:48-01:53] Dr. Pytlowany background information  [01:54-02:52] Why Michigan Medicine created his position [02:53-05:52] The overall impact of drug shortages right now [05:53-07:12] National impact of drug shortages [07:13-10:41] Austin's position helping improving patient care at Michigan Medicine [10:42-12:25] Organizational benefits of individuals or a teams dedicated to drug shortages [12:26-16:41] Other kinds of positions out there [16:42-20:40] Concepts and solutions coming out of this or to market [20:41-22:11] Future for these types of roles in drug shortages [22:12-25:38] Advice for people who want to get into this specialty   Links | Resources:  The One Thing You Need to Know about Drug Shortage Stewardship Drug Shortage Stewardship: Calls to Action for the Interconnected Supply Chain ASHP Current Drug Shortages   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed      

Health system pharmacies are turning to outpatient infusion services to improve financial performance as margins shrink. Dr. Zinkeng Asonganyi, Director of Ambulatory Pharmacy and Infusion Services at University of Texas Medical Branch or UTMB Health discusses the program and it's implications with host Gretchen Brummel, Pharmacy Executive Director with the Vizient Center for Pharmacy Practice Excellence.   Guest speakers:  Zinkeng Asonganyi, PharmD Director of Ambulatory Pharmacy Operations UTMB Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:52-01:38] Dr. Asonganyi background information  [01:39-06:44] What's happening in infusion at UTMB [06:45-12:15] Complexities and logistics of the program [12:16-15:13] Maintaining and growing reimbursement in this time of challenges [15:14-18:33] Biggest opportunities for enhancement or growth   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed    

A big part of total national drug spend is the continuing growth of the specialty drug market. Health systems depend on specialty pharmacy to make up margin losses from other areas. Dr. Vinay Eapen, Senior Manager of Specialty Pharmacy at University of Texas Medical Branch, joins Gretchen Brummel, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence and your program to share a bold approach to starting specialty pharmacy services at an academic medical center.   Guest speakers:  Vinay Eapen, PharmD Ambulatory Specialty Pharmacy Supervisor UTMB – League City   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence     Show Notes:  [00:46-01:09] Dr. Eapen background information  [01:10-01:52] History of the specialty drug market [01:53-02:43] Categorizing specialty drugs [02:44-03:26] When UTMB decided to start a specialty program [03:27-04:18] Building the program [04:19-05:25] Benefits of the program [05:26-06:11] Unexpected issues [06:12-06:54] Where specialty pharmacy is going [06:55-07:37] Advice for other starting specialty pharmacy programs [07:38-08:21] Reasons to start a specialty pharmacy   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Health system margins are shrinking making pharmacy spend a growing opportunity target. MultiCare Health System departs from historical methods with an exciting, multifaceted approach to the issue.  Dr. Tyson Frodin, Assistant Vice President Pharmacy Supply Chain, Rev Cycle, Technology MultiCare Health System-Pharmacy Services, joins Gretchen Brummel, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence and your program host to give his thoughts on this issue.   Guest speakers:  Tyson Frodin, PharmD, MHA, FACHE Assistant Vice President Pharmacy Supply Chain, Rev Cycle, Technology MultiCare Health System-Pharmacy Services   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence     Show Notes:  [00:46-01:31] Dr. Tyson Frodin background information  [01:32-02:39] What drove the need for MultiCare's pharmacy spend initiative [02:40-08:42] Multi-pronged plan for MultiCare's pharmacy spend initiative [08:43-10:20] What surprised MultiCare about the process [10:21-11:25] Outcomes [11:26-13:11] Advice they have for other pharmacies who may wanna attempt something like this [13:12-15:06] What's in the future for MultiCare   Links | Resources:  Coming soon – New Pharmacy Portal and Pharmacy Analytics platform We're excited to announce the launch of our new Pharmacy Portal on March 25th, alongside the rebranding of Vizient Savings Actualyzer – Pharmacy (VSAP) to Pharmacy Analytics. The Pharmacy Portal is designed to be a comprehensive hub, offering a wide range of pharmacy tools and metrics, all accessible in one convenient location. With the rebranding to Pharmacy Analytics, we're introducing upgraded features and functionalities aimed at optimizing contract management, benchmarking spend, evaluating drug shortages and much more. Join our webinar on March 27, Navigating Vizient Pharmacy Analytics with PMO projections and data, to learn more about the features and benefits of our new Pharmacy Portal and rebranded Pharmacy Analytics platform. Plus, we will be hosting deeper dive sessions March 18 through April 5 where you can experience the new tools and ask questions of our pharmacy analytics experts. Learn more and sign up for one or multiple sessions.   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

The 1984 Hatch-Waxman Act codified the 505(b)(2) drug approval pathway and allowed the use of studies from a previously approved drug. To be clear, medications approved via this pathway are not generic molecules of the reference listed drug. They may have similar clinical effects and roles in therapy, but they also bring challenges. Dr. Tyler Wood, System Director of Pharmacy Oncology and Biosimilars, and Pharmacy Executive Director, Carolyn Liptak at Vizient, join Gretchen Brummel, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence and your program host to give an early look.   Guest speakers:  Tyler Wood, PharmD, BCBBS System Director, Pharmacy Oncology and Biosimilars  Providence St. Joseph Health Carolyn Liptak, MBA, BSPharm Pharmacy Executive Director  Vizient    Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:55-01:34] Dr. Tyler Wood background information  [01:35-03:09] How the 505(b)(2) pathway is intended to work [03:10-04:32] Comparisons can we draw from the biologics approval process [04:33-05:53] What the FDA says about which pathway to use [05:54-07:05] What's changed recently in the approval process [07:06-08:09] Can a 505(b)(2) product be rated as a generic equivalent? [08:10 -09:07] How CMS changes are impacting management [09:08-11:23] What our providers can do to plan and act to address these issues [11:24-12:27] What's most concerning moving forward   Links | Resources:  Applications Covered by 505(b)(2) Hospital Outpatient Prospective Payment System: January 2024 Update MLN Matters® Articles Sign-up CMS.gov ASP Pricing Files CMS.gov What's a MAC Drugs@FDA: FDA-Approved Drugs FDA: Overview of the 505(b)(2) Regulatory Pathway for New Drug Applications HCPCS Level II Coding for 505(b)(2)-Approved Drugs or Biologicals – Frequently Asked Questions   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed  

Pneumococcal vaccines have been instrumental in decreasing invasive disease since their introduction in the 1980s. 2021 brought regulatory changes and recent ACIP recommendations were published in the Morbidity and Mortality Weekly Report, also known as MMWR. Dr. John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information shares his insights on these changes with host Gretchen Brummel.      Guest speakers:   John Schoen, PharmD, BCPS Senior Clinical Manager of Evidence-Based Medicine and Drug Information Vizient Center for Pharmacy Practice Excellence      Host:   Gretchen Brummel, PharmD, BCPS   Pharmacy Executive Director   Vizient Center for Pharmacy Practice Excellence     Show Notes:   Recorded in the Fall of 2023 [01:00-03:34] What's new since March 2022 with pneumococcal vaccines  [03:35-06:51] Changes with the adult recommendations [06:52-13:10] New recommendations from CDC as well as published recommendations for adults [13:11-19:05] Recommendations for Pneumococcal vaccines in pediatrics [19:06-21:46] The area of biggest risk moving forward [21:47-24:07] What we are looking at for the future        Links | Resources:   Vizient pneumococcal vaccine side-by-side comparison Click Here ACIP pneumococcal vaccine recommendations Click Here   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Vizient publishes our Pharmacy Market Outlook twice a year. The outlook features drug price projections and key market insights to help support members' strategic planning. Drs. Jeni Hayes and Amanda Frick, both Senior Clinical Managers for Market Intelligence, join Gretchen Brummel, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence and your program host to give an early look.   Guest speakers:  Jeni Hayes, PharmD, MSPharm, BCPS Senior Clinical Manager, Market Intelligence Vizient    Amanda Frick, PharmD, BCPS Senior Clinical Manager, Market Intelligence Vizient    Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence     Show Notes:  [00:42-03:08] Areas of focus 2024 highlighted in this Pharmacy Market Outlook  [03:09-05:35] The table of new and noteworthy approvals and some of the approvals that you were most excited to see [05:36-07:05] Some drugs that you're looking forward to seeing approved in 2024 [07:06-08:25] What are you hearing from our members on their experiences and challenges with cellular and gene therapies? [08:26-10:57] What else is going on in the specialty space [10:58-12:14] Specialty pharmacy sustained growth that we've seen for patients in the acute care space [12:15 -14:39] What's the projection for this edition [14:40-14:24] Where listeners go if they want more detailed information on the outlook   Links | Resources:  Vizient Pharmacy Market Outlook provider link: Click Here Vizient Pharmacy Market Outlook highlights public version: Click Here   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Anti-Microbial Stewardship Programs are critical to optimizing utilization, mitigating resistance, and improving patient outcomes. These programs are continuously refined, and recent updates to The Joint Commission standards provide an opportunity to enhance our approach. Dr. Ripal Jariwala, Infectious Diseases Clinical Pharmacist, and Assistant Clinical Professor at the University of California San Francisco, and Dr. Ethan A. Smith, Clinical Infectious Diseases Specialist at Ronald Reagan UCLA Medical Center, join host Gretchen Brummel to discuss the revised standards and implications for pharmacy.   Guest speakers:  Dr. Ripal Jariwala, PharmD, BCIDP, AAHIVP Infectious Diseases Clinical Pharmacist, and Assistant Clinical Professor UCSF    Dr. Ethan A. Smith, PharmD., BCIDP Clinical Infectious Diseases Specialist Ronald Reagan UCLA Medical Center   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence   Show Notes:  [01:01-01:47] The guests background  [01:48-02:58] Brief update of the recent changes to Antimicrobrial Stewardship [02:59-07:35] Interpreting the new EP-10 Joint Commission standard about financial and IT resources [07:36-11:23] The current landscape on FTEs to support antimicrobial stewardship [11:24-15:13] EP15 on evidence-based use of antibiotics considerations [15:14-18:27] How do you approach meeting the revised standard on data collection analysis and recording for EP20 [18:28 -21:23] Other standards besides the joint commission standards that people need to be aware of [21:24-23:34] Other related work going on in this space [23:35-26:54] More information or other resources to find those items about antimicrobial stewardship   Links | Resources: Knowledge on the Go Podcast: Updates for Antimicrobial Stewardship Standards VHA directive 1031: Click here CDC Updates on Antibiotic Stewardship and Required Antimicrobial Use and Resistance Reporting – On Demand: CDC Updates OnDemand2023 document and Click here to play recording   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

The Drug Supply Chain Security Act was designed to ensure the safety and integrity of our nation's drug supply and prevent counterfeit medications from entering the market.  In this third of a four-part series, Carolyn Liptak and Dwight deVera share their insights on FDA final DSCSA guidance with host Gretchen Brummel and how member providers can be ready.     Guest speakers:  Carolyn Liptak, MBA, BSPharm  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence  Dwight deVera VP of Healthcare Intelligence  Inmar Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:44-01:14] Dwight's background  [01:15-02:20] What Carolyn and Dwight are hearing in the market [02:21-03:39] Carolyn and Dwight's thoughts on taking that stabilization period as an opportunity to wait [03:40-05:22] Meeting the deadline on GLN's [05:23-06:59] Issue with having duplicate GLNs for a single site [07:00-07:43] How Dwight is advising clarity on a timeline with the quarantine process [07:44-09:23] Other tools our members need to know about if they have a suspect product investigation [09:24-10:30] Comments and advice from Dwight and Carolyn   Links | Resources:  Drug Supply Chain Security Act (DSCSA) portal FDA Requests Feedback on Enhanced Drug Distribution Security Implementation Progress Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act (DSCSA) Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act – Compliance Policies   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

RSV infections are not new and have devastating impacts. The recent advent of new prevention strategies has renewed the focus on the disease with a hopeful outlook. For the last 25 years, the only FDA approved product preventing RSV, lower respiratory tract disease, was palivizumab or Synagis, a monoclonal antibody indicated for use in high risk infants children and administered intramuscularly monthly throughout the RSV season. In May, the first ever RSV vaccines were approved, Arexvy and Abrysvo. These two new RSV vaccines were approved for use in adults greater than or equal to 60 years of age. In August this year, one of the RSV vaccines, Abrysvo, also received approval for expanded use for maternal vaccination to prevent RSV lower respiratory tract disease in infants. Nirsevimab or Beyfortus, a new long-acting monoclonal antibody, was approved in July for prevention of RSV lower respiratory tract disease in infants and children. Compared with palivizumab, nirsevimab is indicated for a much broader patient population including recommended use in all infants less than eight months of age, born during or entering their first RSV season. The rollout of nirsevimab has proved challenging due to supply shortages, among other factors. Today we discuss the new RSV prevention strategies, focusing on the pediatric patient population, as well as the recent shortages with nirsevimab. Dr. Deb Bondi, Dr. Nikolai Dahl, as well as Dr. Kyle Hoelting from Vizient join guest host Vizient's John Schoen for today's podcast.   Guest speakers:  Deb Bondi, PharmD, FCCP, BCPS, BCPPS Pediatric Clinical Coordinator, NICU Clinical Pharmacy Specialist, and PGY2 Pediatric Pharmacy Residency Program Director UChicago Medicine, Comer Children's Hospital   Nikolai Dahl, PharmD Utilization and Formulary Program Manager John Muir Health   Kyle Hoelting, PharmD, BCPS Senior Clinical Manager of Drug Shortages and Drug Information Vizient Center for Pharmacy Practice Excellence    Host:  John Schoen, PharmD, BCPS  Senior Clinical Manager of Evidence-Based Medicine and Drug Information Vizient Center for Pharmacy Practice Excellence   Show Notes:  [02:39-04:09] Update on where everything currently stands with the Nirsevimab supply and what led to the shortage [04:10-05:01] Information on whether or not there's going to be additional supply of either the 50 mg or 100 mg syringes later this season [05:02-06:01] Resources related to mitigating this nirsevimab shortages [06:02-10:29] What University of Chicago and John Muir Health are doing with these new RSV vaccines and the new monoclonal antibody, Beyfortus [10:30-13:15] Formulary decisions University of Chicago and John Muir Health make around nirsevimab and palivizumab [13:16-15:24] Organizational preference for the maternal RSV vaccine or nirsevimab [15:25-20:33] Other logistical issues with either nirsevimab or the maternal RSV vaccines, such us scope of practice consideration, stocking of the VFC product in patient education, et cetera [20:34-22:01] Payment of billing issues either University of Chicago or John Muir Health experienced for either nirsevimab or the maternal RSV vaccine [22:02-24:57] Clinical pearls or advice related to these new prevention strategies   Links | Resources: Vizient member RSV resources RSV vaccines in adults side-by-side comparison RSV monoclonal antibodies in pediatrics side-by-side comparison FAQ pediatric RSV prevention strategies Minute Market Insight on nirsevimab shortage Mitigation strategy on nirsevimab shortage   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

With healthcare complexity and workforce challenges increasing across the board, there's opportunity for pharmacies to take on new roles to improve patient care. Dr. Jill Michaud, system director of pharmacy at Aspirus Health, joins us to share their innovative approach to expanding pharmacy services with host Gretchen Brummel.     Guest speakers:  Jill Michaud, PharmD, MS-HA System Director of Pharmacy Aspirus Health Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:49-01:55] Aspirus and Jill's role there [01:56-04:27] Activities that Jill's staff is doing [04:28-06:48] Work they are doing in the oncology space [06:49-07:27] Making Aspirus Health's approach to public relations and marketing activities with regards pharmacy a priority. [07:28-09:17] Is that included in residency recruitment, or more of a surprise when they get there [09:18-11:37] Advice do you have for other pharmacies who may be faced with challenges   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

The Drug Supply Chain Security Act was designed to ensure the safety and integrity of our nation's drug supply and prevent counterfeit medications from entering the market.  In this second of a four-part series, Carolyn Liptak, Eric Marshall, and Josh Bolin share their insights on FDA final DSCSA guidance with host Gretchen Brummel and how member providers can be ready.     Guest speakers:  Carolyn Liptak, MBA, BSPharm  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Eric Marshall  Principal at Leavitt Partners Executive Director of the Partnership for DSCSA Governance   Josh Bolin  Associate Executive Director, Government Affairs and Innovation National Association of Boards of Pharmacy   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence   Show Notes:  [00:55-02:27] Josh and Eric's backgrounds  [02:28-03:36] What we need to know for DSCSA implementation on November 27th [03:37-05:10] NABP view of FDA DSCSA guidance [05:11-07:27] PDG view of FDA DSCSA guidance [07:28-08:23] Next steps for DSCSA compliance that our members should be focusing on [08:24-11:11] Why it is important to have documented policies and procedures to ensure compliance [11:12-12:28] Where organizations that need help with creating those policies and procedures go [12:29-15:24] How the 24-hour time frame is defined since medications are not traced within a hospital [15:25-18:17] DSCSA regulatory responsibilities are shared between the FDA and state boards of pharmacy [18:18-21:26] How we account for traceability across state lines and what should we expect in the future [21:27-23:49] Some complexities here especially around 340B medications [23:50-24:54] Where verification has to occur: data flowing from the manufacturer to the covered entity, but the product is flowing to the actual contracted pharmacy [24:55-26:30] Last thoughts on how our members can be set for DSCSA   Links | Resources: Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act (DSCSA) Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act – Compliance Policies NABP Links: https://nabp.pharmacy https://nabp.pharmacy/pulse     Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Intranasal administration of medications is on the rise for both on and off label uses. Dr. Mark Donaldson, Associate Principal and Dr. Philippe Mentler Senior Consulting Director, both at Vizient join host Gretchen Brummel for two episodes, sharing details on these drugs, their actions and indications.   Guest speakers: Mark Donaldson, BSP, RPH, PHARMD, FASHP, FACHE Associate Principal Vizient Philippe Mentler, PHARMD, BCPS Senior Consulting Director Vizient Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [00:33 - 02:50] Why you would choose intra-nasal administration of an agent over some of the other non-oral or non-IV routes [02:51 - 6:05] Some practical considerations people should be aware of, particularly when not to use these agents [6:06 - 7:12] Some of the implications for the pediatric population [7:13 - 12:10] What we have to look forward to in the future in this space [12:11 - 13:46] What our frontline pharmacy staff should know about these medications   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed  

Intranasal administration of medications is on the rise for both on and off label uses. Dr. Mark Donaldson, Associate Principal and Dr. Phillipe Mentler Senior Consulting Director, both at Vizient join host Gretchen Brummel for two episodes, sharing details on these drugs, their actions and indications.   Guest speakers: Mark Donaldson, BSP, RPH, PHARMD, FASHP, FACHE Associate Principal Vizient Phillipe Mentler, PHARMD, BCPS Senior Consulting Director Vizient Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [01:16 - 03:46] Why the nose is a good target for medication administration [03:47 - 5:49] Some things you need to consider when administering medications intra-nasally [5:50 - 8:13] Some of the labeled and off-label intra-nasal medications and their indications [8:14 - 9:15] What we should be thinking about in terms of safety [9:16 - 10:06] Wrong route, have you seen that in your practice, or have there been reports of that in the literature [10:07 - 15:10] How some of these drugs are used in dental medicine   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Pharmacy residents can experience burnout during their training, and as preceptors, it is our responsibility to work to prevent this. Practicing Mindfulness can help. Glenn Kuz, Clinical Pharmacist at UW Medicine and certified mindfulness meditation practitioner joins Gretchen Brummel to discuss a formal training program he developed for the residents at UW Medicine, providing a safe patient care environment and improving their own wellbeing.   Guest speakers: Glenn Kuz, PharmD Clinical Pharmacist  UW Medicine Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [00:49 - 01:37] Glenn's background [01:38 - 3:50] How Glenn got interested in using Mindfulness Practice to help pharmacy residents during their training [3:51 - 5:48] Glenn's training program [5:49 - 8:54] Literature that supports Glenn's program [8:55 - 10:51] The impact of the program [10:52 - 12:22] Future plans [12:23 - 13:13] Glenn's recommendations for other pharmacy programs looking to start a similar program   Links | Resources: https://www.rickhanson.net/ Resilient by Rick Hanson, PhD gkuw@uw.edu   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Vizient recently published a paper on the impact of oncology drug shortages for patients and provider members. Drs. Carina Dolan and Jeni Hayes share their insights of the causes and how to improve things moving forward with host Gretchen Brummel.     Guest speakers:  Carina Dolan, PharmD, MS, BCOP AVP of Market Intelligence  Vizient Pharmacy Solutions  Jeni Hays, PharmD, MSPharm, BCPS  Senior Clinical Manager, Market Intelligence Vizient Pharmacy Solutions   Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [00:48-01:52] Drugs included in shortage of cancer drugs report [01:53-02:58] How we define drug shortages [02:59-04:03] Specific event that precipitated the oncology drug shortage [04:04- 05:39] Overall impact on the sales for these medications [05:40-07:25] What demand are we seeing for these medications [07:26-08:23] How Vizient Pharmacy Program participants have been affected [08:24-09:59] Looking at the shortage severity and its impact on Vizient Pharmacy Program participants [10:06-12:13] How we improve things moving forward [12:14-13:49] What front line pharmacy staff should know about these shortages   Links | Resources:  Evaluating the impact of the oncology drug shortage white paper Evaluating the impact of the oncology drug shortage fact sheet Vizient: Lack of Information Across Supply Chain Exacerbating Oncology Drug Shortage press release Webinar: Oncology insights: new therapies and drug shortages Drug shortage: Oncology agents mitigation strategy   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed        

The Drug Supply Chain Security Act was designed to ensure the safety and integrity of our nation's drug supply and prevent counterfeit medications from entering the market.  Carolyn Liptak shares her insights on DSCSA with host Gretchen Brummel and how member providers can be ready.   Guest speakers:  Carolyn Liptak, MBA, BSPharm  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence  Host:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence    Show Notes:  [01:01-02:32] The DSCSA at its core  [02:33-06:25] The different responsibilities of manufacturers, repackagers, wholesalers, and distributors [06:26-08:47] What things should have been taken care of already [08:48-10:34] What is a GLN? How do I get one, who needs one? [10:35-11:39] What Vizient has done to help our provider members get ready for this [11:40-14:26] What happens on November 27th, 2023 [14:27-16:11] The impact of the recent FDA announcement   Links | Resources:  Vizient DSCSA page  - Click Here How to obtain GLNs - Click Here DSCSA SBS - Click Here   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed  

In our last episode of VerifiedRx, Lisa Hanlon, Medication Safety and Compliance Specialist at Penn State Health, Hershey Medical Center and Heart Rhythm Meditation practitioner, shared the connection between medication safety and meditation by exploring the science, methods and rationale around cultivating stress resilience strategies such as meditation and their impact on not only personal but also professional performance. Today, Gretchen welcomes Lisa back to explore meditation for newcomers and lead an example meditation session.   Guest speakers: Lisa M Hanlon, BS Pharm, RPh Medication Safety and Compliance Specialist Penn State Health, Milton S. Hershey Medical Center   Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [00:33 - 13:17] Lisa's guides a meditation session   Links | Resources: iamHeart website Connecting With Heart - iamHeart   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Medication safety is top of mind for all pharmacy professionals, and being present and resilient is integral to safe and effective patient care. Lisa Hanlon, Medication Safety and Compliance specialist at Penn State Health, Hershey Medical Center and Heart Rhythm Meditation practitioner joins Gretchen Brummel to walk us through the methods, science and reasoning behind mindfulness and meditation as key tools for providing a safe patient care environment and improving our own wellbeing.   Guest speakers: Lisa M Hanlon, BS Pharm, RPh Medication Safety and Compliance Specialist Penn State Health, Milton S. Hershey Medical Center   Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [00:45 - 02:13] Lisa's background [02:14 - 3:57] How Lisa started meditation and applied it in her work [3:58 - 5:37] How Lisa connects mindfulness and medication safety [5:38 - 8:06] The differences between meditation and mindfulness [8:06 - 9:47] Key things Lisa shares about meditation and mindfulness [9:48 - 12:04] Examples of things that we could avoid just by being more present in our work [12:05 - 13:11] Lisa's recommendations on how to get started with a practice [13:12 - 13:51] What Lisa wants frontline pharmacy staff to know about meditation   Links | Resources: iamHeart website Connecting With Heart - iamHeart   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Vizient Pharmacy Vision Awards celebrate the values and achievements of our pharmacy members. 3 winners of the 2022 Excellence in Public Policy Award, Jacqueline Blake, Drs. Leeann Miller and Marjorie Lazarre, all from Yale New Haven Health, join Gretchen Brummel, Pharmacy Executive Director in the Center for Pharmacy Practice Excellence at Vizient, and your program host to discuss advancing pharmacy practice through public policy. Guest speakers: LeeAnn Miller, PharmD, MS, CPEL Vice President, Chief Pharmacy Officer Yale New Haven Health   Marjorie Lazarre, PharmD, MBA  Associate Chief Pharmacy Officer Corporate Pharmacy Services Yale New Haven Health   Jacqueline Blake, Esq Senior Government Relations Officer Yale New Haven Health   Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence Show Notes: [00:42-01:48] Amber, Marie and Steph backgrounds [01:49-03:11] Why advocacy is so important [03:12 - 05:06] How to justify focusing on advocacy [05:07- 06:36] How to get started in advocacy [06:37-08:31] Getting away from, "We've always done it this way [08:31 - 12:43] Changes in advocacy over their careers [12:44 - 13:54] Maintaining momentum [13:55 - 17:33] Real world wins and examples of successes [17:34 - 21:05] Partners to propel their messages forward [21:06 - 23:34] Things folks should look out for [23:35 - 25:42] Their advice around advocacy [25:43 - 26:25] Future plans Links | Resources: Vizient Pharmacy Vision Awards Overview document About the program 2022 award winners Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Stitcher Android RSS Feed

Vizient Pharmacy Vision Awards celebrate the values and achievements of our pharmacy members. 3 winners of the 2022 Excellence in Public Policy Award, Drs. Amber Zaniewski, Steph Luon, and Marie Renauer, all from Yale New Haven join Gretchen Brummel, Pharmacy Executive Director in the Center for Pharmacy Practice Excellence at Vizient, and your program host to discuss advancing pharmacy practice through public policy. Guest speakers: Steph Luon, PharmD, BCPS, BCACP Manager, Ambulatory Clinical Pharmacy Services Yale New Haven Hospital Marie M. Renauer, PharmD, MBA, BCACP  Associate Director, Ambulatory Clinical Pharmacy Services Yale New Haven Hospital Amber Zaniewski, PharmD, BCPS, BCCCP System Director, Clinical Pharmacy Services Yale New Haven Hospital, Corporate Pharmacy Services Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence Show Notes: [00:43-01:28] Amber, Marie and Steph backgrounds [01:29-5:17] Identifying the need for public policy changes [5:18 - 06:36] Key stakeholders they partnered with [06:37-11:58] How the process unfolded and results [11:59-12:55] Challenges along the way [12:56 - 15:59] Positive impacts [16:00 - 18:12] Advice for Pharmacy Professionals [18:13 - 18:41] Future plans Links | Resources: Vizient Pharmacy Vision Awards Overview document About the program 2022 award winners Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Stitcher Android RSS Feed

Jeni Hayes and Shannon Holden share insights on the Summer 2023 Vizient Pharmacy Market Outlook with host Gretchen Brummel. Jeni, and Shannon discuss the outlook's projection, and ways that frontline staff can use the report.   Guest speakers:  Jeni Hayes, PharmD, MSPharm, BCPS  Senior Clinical Manager for Pharmacy Outcomes   Vizient Center for Pharmacy Practice Excellence  Shannon Holden, PharmD, BCACP, CACP  Senior Clinical Manager for Ambulatory  Vizient Center for Pharmacy Practice Excellence  Moderator:  Gretchen Brummel, PharmD, BCPS  Pharmacy Executive Director  Vizient Center for Pharmacy Practice Excellence  Show Notes:  [00:45-01:37] Enhancements and improvements in the Pharmacy Market Outlook this summer  [01:38-02:24] Hot topics for this edition of the PMO  [02:25-03:36] Expectations of adalimumab biosimilars  [03:37-5:03] Spending impact on medications to treat autoimmune and inflammatory conditions  [5:04-6:50] Insight into the new cardio-metabolic and neurology sections  [6:51-8:43] Should we expect to see continued growth in spending on oncology agents  [8:44-10:31] Final projection number for this edition  [10:32-12:38] How frontline staff can use PMO in their work  [12:39-13:05] Where to get more detailed information on PMO  Links | Resources:  Vizient Pharmacy Market Outlook Member link: Click Here Click here Vizient Pharmacy Market Outlook highlights public version: Click Here  Semaglutide: weighing the pros and cons for use in pediatrics  Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Stitcher Android RSS Feed